Tag: European Medicines Agency (EMA)

Palforzia Capsules with Logo

Results of Aimmune’s Pivotal Phase 3 European Trial of PALFORZIA® Published...

Peanut-allergic patients treated with Palforzia showed desensitization to peanut protein with a predictable safety profile at nine months